- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04765826
Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maha Alsayed Alrashidy, MD
- Phone Number: +201024524412
- Email: mahaalrashidy87@yahoo.com
Study Contact Backup
- Name: I
Study Locations
-
-
-
Alexandria, Egypt
- Recruiting
- Alexandria Faculty of Medicine
-
Contact:
- Maha Alrashidy, MD
- Phone Number: +201024524412
- Email: mahaalrashidy87@yahoo.com
-
Contact:
- Carmen Ibrahiem farid amin, Ph.D
- Phone Number: +201222966670
- Email: carmen271173@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients of either gender aged more than 18 years old, with stable resistant non-segmental vitiligo will be included.
Stability is defined in terms of:
- Absence of new lesions or extension of preexisting lesions prior to presentation for the last 6 months.
- Absence of koebner phenomenon, confetti lesions or hypopigmented lesions, or lesions with ill-defined borders during this same time period.
Absence of activity signs by dermoscopic examination which includes :
- Ill-defined or trichrome border.
- Micro-Koebner's phenomenon.
- Tapioca sago appearance.
- Starburst appearance.
- Comet tail appearance.
- Altered pigment network. Resistance to treatment is defined in terms of not responding or those responding poorly to administered treatment (<25% repigmentation according to VASI score) over the last 3 months, especially in patients having lesions on glabrous skin or those with lesions showing leukotrichia.
Exclusion Criteria:
Cases of active, the progressive disease having any of the features of activity listed above during the last 6 months.
Patients with regressive disease showing evidence of repigmentation under administered therapy.
Patients with segmental vitiligo or vitiligo affecting more than 70% body surface area.
Patients with associated autoimmune diseases or any other comorbidity. Patients with a tendency towards hypertrophic scars or keloid formation. Pregnant and breast-feeding females. Patients with psychological instability and unrealistic expectations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: high dose oral steroids
(20 patients) will receive high dose oral mini pulse steroids (dexamethasone 5 mg on two consecutive weekly days for 3 months).
|
All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included. . Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local infiltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site |
Experimental: low dose oral steroids
(20 patients) will receive low dose oral mini pulse steroids (2.5mg dexamethasone on two consecutive weekly days for 3 months
|
All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included. . Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local infiltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site |
Experimental: topical treatment
(20 patients) chosen lesions of comparable size and location in each patient in this group will receive either; super potent topical steroids once every other day, Tacrolimus ointment twice daily for 3 months, or nothing to serve as a control.
|
All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included. . Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local infiltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of repigmentation and signs of reactivation
Time Frame: 9 months
|
assessment of repigmentation will be performed by two blinded dermatologists using a 5-point scale ;grade 0(no repigmentation),grade 1(1%-5%),grade 2(6%-25%),grade3(26%-50%),grade4(51%-75%),grade5(76%-100%) |
9 months
|
Evaluation of type, pattern and extent of re pigmentation
Time Frame: 9 months
|
serial photography will be done to evaluate type, pattern and extent of re pigmentation
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Carmen brahiem farid amin, Ph.D, Assistant professor of dermatology faculty of medicine .University of Alexandria
- Study Director: Ai Ahmed fouad El Eriny, Ph.D, Professor of dermatology faculty of medicine .University of Alexandria
- Study Director: Eman Hamed El Morsy, Ph.D, Professor of dermatology faculty of medicine .University of Alexandria
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mahaderma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoChina, Japan, Canada, Spain, United States, Hungary, Poland, Slovakia
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on Autologous mini punch grafting
-
Hartford HospitalRecruiting
-
Postgraduate Institute of Medical Education and...Unknown
-
King Edward Medical UniversityCompletedHyperpigmentationPakistan
-
Nanjing Medical UniversityCompletedBreast Implantation
-
Nanjing UniversityUnknown
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruiting
-
Alexandria UniversityRecruiting
-
Netherlands Institute for Pigment DisordersAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Avita MedicalTerminated
-
Stanford UniversityWithdrawn